Thermo Fisher Scientific Inc. (NYSE:TMO) on Thursday reported first-quarter 2026 adjusted earnings of $5.44 per share, beating the street view of $5.24.

The life science giant’s quarterly sales of $11.01 billion increased 6% year-over-year, beating the analyst consensus estimate of $10.85 billion. Organic revenue growth was 1%.

Segment Performance Shows Strength In Bioproduction

Life Sciences Solutions sales increased 12.6% to $2.64 billion. Analytical Instruments sales were flat at $1.72 billion.

Read Also:

Seer Joins Thermo Fisher Tools In Large-Scale Proteomics Effort

Specialty Diagnostics revenues reached $1.14 billion, and Laboratory Products and Biopharma Services sales were up 7% to $6.04 billion.

The Pharma and Biotech segment delivered mid-single-digit growth during the quarter, driven ...